Nonmem version 7.2 foce 1

Pharmacokinetic analysis was conducted by non-linear mixed-effects modeling using NONMEM^® Version 7.2 (FOCE+I; ICON Development Solutions, Ellicott City, MD, USA) and PsN^® Version 4.6.0. Pirana^® software was used as an interface between NONMEM^®, R (version 3.2.2) and Xpose (version 4).

Pharmacokinetic analysis was conducted by nonlinear mixed-effects modeling using NONMEM version 7.2 (FOCE + I; ICON Development Solutions, Ellicott City, MD, USA) and PsN version 4.6.0. Pirana software was used as an interface between NONMEM, R (version 3.2.2) and Xpose (version 4). Base model and covariate model development was conducted as described previously [17 (link)]. The following demographic, clinical, and genetic characteristics were evaluated as potential covariates: weight, height, sex, age, ethnicity, co-medication (glucocorticoids and calcium channel blockers), glucocorticoid dose, CYP3A4 and CYP3A5 genotype, primary kidney disease, number of transplantations, renal replacement therapy prior to transplantation (pre-emptive, peritoneal dialysis, or hemodialysis), donor status (living or deceased), human leukocyte antigen mismatches, time post-transplant, hematocrit, creatinine, estimated glomerular filtration rate (Schwartz formula [28 (link)]), aspartate aminotransferase, albumin, C-reactive protein, and total protein.